Sophion Bioscience’s Post

Why should you attend ICMS® in Boston? Here’s a word of advice from Principal Scientist Edward Humphries, a frequent ICMS attendee: “𝗔𝘀 𝗮𝗻 𝗶𝗼𝗻 𝗰𝗵𝗮𝗻𝗻𝗲𝗹 𝗯𝗶𝗼𝗹𝗼𝗴𝗶𝘀𝘁 𝘄𝗼𝗿𝗸𝗶𝗻𝗴 𝗶𝗻 𝗱𝗿𝘂𝗴 𝗱𝗶𝘀𝗰𝗼𝘃𝗲𝗿𝘆, 𝗜𝗖𝗠𝗦 𝗶𝘀 𝗮 𝗺𝘂𝘀𝘁-𝗮𝘁𝘁𝗲𝗻𝗱 𝗲𝘃𝗲𝗻𝘁 𝗳𝗼𝗿 𝗺𝗲 𝗲𝘃𝗲𝗿𝘆 𝘆𝗲𝗮𝗿. 𝗧𝗵𝗲 𝗹𝗲𝗰𝘁𝘂𝗿𝗲𝘀 𝗰𝗼𝘃𝗲𝗿 𝗮 𝘄𝗶𝗱𝗲 𝗿𝗮𝗻𝗴𝗲 𝗼𝗳 𝘁𝗼𝗽𝗶𝗰𝘀, 𝗳𝗿𝗼𝗺 𝗶𝗻-𝗱𝗲𝗽𝘁𝗵 𝗲𝗹𝗲𝗰𝘁𝗿𝗼𝗽𝗵𝘆𝘀𝗶𝗼𝗹𝗼𝗴𝘆 (𝘄𝗲 𝗲𝘃𝗲𝗻 𝘀𝗮𝘄 𝘀𝗼𝗺𝗲 𝘀𝗶𝗻𝗴𝗹𝗲-𝗰𝗵𝗮𝗻𝗻𝗲𝗹 𝗿𝗲𝗰𝗼𝗿𝗱𝗶𝗻𝗴𝘀 𝗹𝗮𝘀𝘁 𝘆𝗲𝗮𝗿) 𝘁𝗼 𝗯𝗿𝗼𝗮𝗱𝗲𝗿 𝗶𝗻𝗱𝘂𝘀𝘁𝗿𝘆 𝘂𝗽𝗱𝗮𝘁𝗲𝘀 𝗳𝗿𝗼𝗺 𝗰𝗼𝗺𝗽𝗮𝗻𝗶𝗲𝘀 𝗹𝗶𝗸𝗲 𝗔𝘀𝘁𝗿𝗮𝗭𝗲𝗻𝗲𝗰𝗮 𝗮𝗻𝗱 𝗔𝘂𝘁𝗶𝗳𝗼𝗻𝘆 𝗶𝗻 𝗿𝗲𝗰𝗲𝗻𝘁 𝘆𝗲𝗮𝗿𝘀. 𝗪𝗼𝗿𝗸𝗶𝗻𝗴 𝗮𝘁 Maxion Therapeutics, 𝗮𝗻 𝗶𝗼𝗻 𝗰𝗵𝗮𝗻𝗻𝗲𝗹 𝗮𝗻𝗱 𝗚𝗣𝗖𝗥-𝘁𝗮𝗿𝗴𝗲𝘁𝗶𝗻𝗴 𝗱𝗿𝘂𝗴 𝗱𝗲𝘃𝗲𝗹𝗼𝗽𝗺𝗲𝗻𝘁 𝗰𝗼𝗺𝗽𝗮𝗻𝘆, 𝗜𝗖𝗠𝗦 𝗽𝗿𝗼𝘃𝗶𝗱𝗲𝘀 𝗮 𝗴𝗿𝗲𝗮𝘁 𝘄𝗮𝘆 𝘁𝗼 𝗺𝗲𝗲𝘁 𝗰𝗼𝗹𝗹𝗮𝗯𝗼𝗿𝗮𝘁𝗼𝗿𝘀 𝗮𝗻𝗱 𝗹𝗲𝗮𝗿𝗻 𝗳𝗿𝗼𝗺 𝗹𝗲𝗮𝗱𝗶𝗻𝗴 𝗮𝗰𝗮𝗱𝗲𝗺𝗶𝗰𝘀 𝗶𝗻 𝗮 𝗿𝗲𝗹𝗮𝘅𝗲𝗱, 𝗶𝗻𝘁𝗶𝗺𝗮𝘁𝗲 𝘀𝗲𝘁𝘁𝗶𝗻𝗴 𝘄𝗵𝗲𝗿𝗲 𝗶𝗱𝗲𝗮𝘀 𝗳𝗹𝗼𝘄 𝗮𝗻𝗱 𝗽𝗮𝗿𝘁𝗻𝗲𝗿𝘀𝗵𝗶𝗽𝘀 𝗮𝗿𝗲 𝗰𝗿𝗲𝗮𝘁𝗲𝗱.” If you haven't registered for the event, you can sign up now here: https://ow.ly/wP6h50SC63a Our ICMS® brings together researchers, scientists, and industry professionals from around the world to exchange ideas, share the latest advancements, and explore new frontiers in ion channel modulation. The event will feature keynote speakers, poster presentations, and excellent networking opportunities. We look forward to spending two days together filled with inspiring talks and discussions. Don't miss out – sign up now while seats are still available. The symposium fills up quickly. #ICMS #Qube384 #QPatch #QPatchCompact #AutomatedPatchClamp #IonChannels #DrugDiscovery #Electrophysiology #Sophion

"With the right design you can do fewer experiments and end up with the same results." Marie GERUS-DURAND explains how moving from one-factor-at-a-time experiments to modern multifactor DOE significantly accelerated the development of clinical trial protocols. At Cerba Research, this shift has enabled faster, high-quality results for clients. Learn more about how DOE can optimize processes: https://go.jmp/3XSADVg #JMP #TimeToInnovate #ClinicalTrials #pharma #designofexperiments

Excited for my first #PEGSEurope presentation as part of the Bruker Biosensors team about the biophysical characterization of Antibodies and Antibody-Drug-Conjugates on Wednesday, November 6, at 3.05 pm in Room 4! Antibody-drug conjugates (ADCs) offer a targeted approach to cancer therapy by using monoclonal antibodies to deliver cytotoxic agents to tumor cells. However, their complexity poses challenges in optimizing pharmacokinetics, efficacy, and safety. We present three biophysical tools to enhance ADC development: high-throughput SPR for candidate ranking, switchSENSE for analyzing avidity and ternary complexes, and scIC for real-time kinetics on cells. These techniques accelerate drug discovery with precise biophysical profiling.

🚀 Exciting News from the DTI Foundation's Research & Development Department! 🚀 Our main goal? Making it easier for research centers, companies, and universities to access high-quality human biological samples for their basic and pre-clinical research projects. 🌟 Here's why we are so proud of offering our servicies in this field:  🔬 Better Research: High-quality human samples lead to better in-vitro models for drug testing and advanced therapies projects, which also reduce the use of animal models in research.  🏥 Hospital & Biobank Collaboration: Hospitals and biobanks can contribute with residual tissue samples from their routine clinical work, helping to advance research without disrupting their daily operations.  💡 Mutual Benefits: Hospitals not only aid in crucial research but also gain resources to support their own projects.   Follow us to know more about our activity! Read more about what we do here 👉 https://lnkd.in/dfCGYf2x

Check out the latest Outcome index tracker, transaction highlights, and strategic analysis from Outcome Capital's #lifesciences deal team. - Targeted protein degradation therapies, in the form of molecular glues or degrader antibody conjugates, continue to catch the eye of both investors and #biopharma partners as an alternative form of #cancertherapeutics - Ginkgo Bioworks completes #diagnostics spending spree through a flurry of #acquisitions to strengthen foothold in genetic medicine capabilities - Fractyl Health breaks #medtech public market drought with #ipo debut - #strategicinsights from Outcome Capital industry expert on Viking Therapeutics, Inc. potential to shake up the #glp1 market and dethrone #pharmaceutical giants currently dominating obesity drug race 

It's really great to see the new Vernalis website launched. The site has had a major update, and now gives a good overview of our capabilities and the ways in which we can work with you to support your drug discovery programs. If you're interested in Hit ID, FBDD, DEL, biophysics or just tapping into over 25 years of deep drug discovery expertise at Vernalis, have a look at www.vernalis.com or drop me a message. #drugdiscovery #FBDD #DEL #HitID #biophysics

We continue to feature the most popular and impactful articles published in 2023 in our journal, Antibody Therapeutics (2022 CiteScore: 6.4). The title of the 8th article we’d like to feature is “A mammalian cell display platform based on scFab transposition”. The authors developed an efficient mammalian cell display platform for antibody discovery and development in an scFab format without requiring prior enrichment by microbial display technologies, based on PiggyBac transposition. The two co-corresponding authors are Dr. Christoph Rader and Dr. Haiyong Peng who were then at The Herbert Wertheim UF Scripps Institute for Biomedical Innovation & Technology, University of Florida. Antibody Therapeutics (2022 CiteScore: 6.4) is the official journal of Chinese Antibody Society (CAS), a non-profit, non-government global professional organization with focus upon antibody-based therapeutics. CAS’s 2024 Annual Conference will take place in Cambridge, MA, USA, on Saturday, May 11, 2024. The theme of this conference is “Beyond Borders: Advancements in Antibody-Based Therapeutics in Uncharted Territories". You are welcome to register for the conference right NOW via the following link. https://lnkd.in/ecmFPA4v   #antibodies #antibody #antibodytherapeutics #mabs #mab #antibodydiscovery #biologics #annualmeeting #annualconference 

Today's the day! 🎉 Join us for the 2nd Biophysical Summit - Exploring New Paths in Biophysical Characterization, hosted by KBI Biopharma and Applied Photophysics. See you there! #BiophysicalSummit #KBI #AppliedPhotophysics

One week after the #ECM2024 conference, and I am still buzzing with excitement from all the stimulating talks that were held. I have primarily worked on immune cells in infectious diseases, and had a small stint working on fibroblasts as my first job after my masters. I managed to connect with two old colleagues from those days, and see all the work they and their teams have been working on for the last two decades. Whilst cells are important in health and disease, the structure that maintains the tissues holds valuable information for disease stratification, disease progression, responsiveness to treatment, and many other aspects of disease pathology and response. The potential in measuring matrix proteins and observing the patterns of expression, we can learn a lot about patient populations and the heterogeneity there is. We are not clones, not every person responds the same. Understanding our differences and similarities can help pharma screen for the right patients, and identify populations that need novel therapeutics. I am a convert. The matrix is the most fascinating and important structure in understanding pathologies and finding solutions. 😉 Watch the video to get inspired for 2026, then book your tickets and join us! The Extracellular Matrix Pharmacology Congress #science #ExtraCellularMatrix #ECM2026 #pharmacology #drugdiscovery